Glaxo wins FDA nod for four-strain flu vaccine

GlaxoSmithKline ($GSK) nabbed FDA approval for its new influenza vaccine Fluarix Quadrivalent, designed to protect against four viral strains, rather than the usual three; the shots will be available for the 2013-14 flu season. Report | Special Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.